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Hepatocyte nuclear factor 4  (HNF4 ) is a member of the nuclear receptor
superfamily that plays a central role in organ development and metabolic
functions. Mutations on HNF4  cause maturity-onset diabetes of the young
(MODY), a dominant monogenic cause of diabetes. In order to understand the
molecular mechanism of promoter recognition and the molecular basis of
disease-causing mutations, the recombinant HNF4  DNA-binding domain was
prepared and used in a study of its binding properties and in crystallization with
a 21-mer DNA fragment that contains the promoter element of another MODY
gene, HNF1 . The HNF4  protein displays a cooperative and speciﬁc DNA-
binding activity towards its target gene-recognition elements. Crystals of the
complex diffract to 2.0 A ˚ using a synchrotron-radiation source under cryogenic
(100 K) conditions and belong to space group C2, with unit-cell parameters
a = 121.63, b= 35.43, c= 70.99 A ˚ ,  = 119.36 . A molecular-replacement solution
has been obtained and structure reﬁnement is in progress. This structure and the
binding studies will provide the groundwork for detailed functional and
biochemical studies of the MODY mutants.
1. Introduction
Hepatocyte nuclear factor 4  (HNF4 ) is a tissue-speciﬁc transcrip-
tion factor that plays an essential role in early vertebrate develop-
ment and embryonic survival. It regulates the expression of a wide
variety of essential genes, including those involved in liver and
pancreatic cell differentiation (Li et al., 2000; Odom et al., 2004),
embryogenesis and early development (Duncan et al., 1994; Lausen et
al., 2000), glucose metabolism (Stoffel & Duncan, 1997), lipid
homeostasis (Hayhurst et al., 2001) and amino-acid metabolism
(Schrem et al., 2002). Mutations in HNF4  cause a dominantly in-
herited form of diabetes known as maturity-onset diabetes of the
young (MODY; Yamagata et al., 1996). These mutations cause the loss
of function of the gene product (Lausen et al., 2000), which leads to
impaired insulin secretion and defects in metabolic pathways (Miura
et al., 2006).
HNF4  is a prototypical member of a unique nuclear receptor
superfamily (NR2A1; Nuclear Receptors Nomenclature Committee,
1999) and exclusively functions as a homodimer (Jiang et al., 1995),
despite its sequence homology to retinoic X receptor (RXR), which
can readily heterodimerize with a related nuclear receptor (Szanto et
al., 2004). HNF4  consists of distinctive functional domains including
a DNA-binding domain (DBD), a ligand-binding domain (LBD) and
additional domains with transcription-activation functions (AF;
Schrem et al., 2002). However, the identity of its bona ﬁde ligand is
still under dispute (Hertz et al., 1998; Petrescu et al., 2005), even
though its apparent ligand has been identiﬁed from structural studies
(Dhe-Paganon et al., 2002; Wisely et al., 2002). HNF4 -DBD contains
two zinc-ﬁnger motifs that speciﬁcally recognize and bind as a
homodimer to a direct repeat of two hexameric half-sites separated
by one (DR1; in the majority) or two nucleotides (DR2) (Jiang et al.,
1995; Rajas et al., 2002). Five MODY1 missense mutations (on four
different residues) are found within the region of our HNF4 -DBD
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All rights reservedconstruct (Fig. 1a) and an additional MODY mutation is found in the
HNF4 -binding site within the promoter of another MODY
(MODY3) culprit gene HNF1  (Fig. 1b; Gragnoli et al., 1997).
Analysis of the structural consequences of each amino-acid substi-
tution should be instructive as to the functional role of each residue.
In order to elucidate the molecular basis of HNF4  function and the
monogenic causes of diabetes, we have prepared and crystallized the
human HNF4  DNA-binding domain in complex with a high-afﬁnity
HNF1  promoter element containing the HNF4  recognition
sequence.
2. Materials and methods
2.1. Construction, expression and purification of HNF4a
DNA-binding domain
The cDNA harboring the full-length human HNF-4 B splice
variant (Kritis et al., 1996) was a kind gift from Dr Steve Shoelson of
Joslin Diabetes Center. A fragment of human HNF4  cDNA (amino
acids 46–126) was subcloned by standard PCR into a pET41a vector
(GE Healthcare). HNF4  was overexpressed in Escherichia coli
BL21-Gold (Novagen) with induction by 0.5 mM IPTG at an OD600
of 0.8–1.0 at 310 K and harvested after culturing for an additional
3–4 h. No zinc solution was added during the puriﬁcation since there
should be a sufﬁcient amount of Zn atoms in the medium to be
incorporated into the protein. The cells were lysed by sonication and
the expressed GST-fusion proteins were isolated with the use of
glutathione-agarose beads (Invitrogen) in bulk plus washing in the
presence of 0.6 M NaCl to prevent nonspeciﬁc binding to bacterial
DNA. HNF4  was released by thrombin digestion from the resin
after overnight incubation at 277 K and was further puriﬁed by ion-
exchange chromatography (Mono-S FPLC). Thrombin digestion
produced a two-residue remnant (Gly-Ser) at the N-terminal end
(Fig. 1a). The puriﬁed protein was estimated to be at least 98% pure
as judged by staining with Coomassie on 8–25% gradient SDS–PAGE
gel (Fig. 2). Fractions were pooled and stored at 193 K as a 10%(v/v)
glycerol stock.
2.2. Gel filtration of HNF4a DNA-binding domain
Gel ﬁltration was performed on a Superdex 75 HR 10/30 column
(GE Healthcare) equilibrated with running buffer containing 20 mM
Tris pH 7.5, 200 mM NaCl, 1 mM EDTA and 10 mM 2-mercapto-
ethanol. Elution was performed at a ﬂow rate of 0.5 ml min
 1.T h e
apparent molecular weight of HNF4 -DBD was determined using
the same column calibrated previously with a range of reference
proteins (Bio-Rad): thyroglobulin (670 kDa), bovine  -globulin
(158 kDa), chicken ovalbumin (44 kDa), equine myoglobin (17 kDa)
and vitamin B12 (1.4 kDa). Blue dextran was used to determine the
void volume of the column.
2.3. Preparation of DNA oligomers
Tritylated oligonucleotides were purchased from the Midland
Certiﬁed Reagent Company (Midland, Texas, USA) and further
puriﬁed by reverse-phase HPLC on a C8 XTerra prep column
(Waters) using a linear 5–50%(v/v) acetonitrile gradient in 50 mM
triethylamine acetate buffer pH 7.0. Excess mobile phase containing
acetonitrile was removed using HiTrapQ (GE Healthcare) and the
trityl groups were removed with 80%(v/v) acetic acid. The depro-
tected oligonucleotides were precipitated with 75%(v/v) ethanol,
dissolved in water for concentration measurement by A260 and
lyophilized before storage at 193 K. Double-stranded DNAs were
generated for crystallization by heating equimolar amounts of
complementary oligonucleotides to 358 K for 10 min and slowly
cooling to 277 K. The annealing buffer condition was 20 mM Tris pH
8.0, 200 mM NaCl and 1 mM EDTA.
2.4. Electrophoretic mobility-shift assay (EMSA)
Single-stranded oligonucleotides 1 and 2 (Fig. 1b) were dissolved in
10 mM Tris (pH 7.5 at 293 K) and 1 mM EDTA. Oligonucleotide 1
was 50-end labeled with
32P as described by Maxam & Gilbert (1977).
Labeled oligonucleotide 1 was mixed with a 1.1-fold molar excess of
oligonucleotide 2 and the samples were heated to 363 K and cooled
slowly to 293 K. DNAwas transferred by dialysis into binding buffer
[10 mM Tris pH 8.0, 1 mM EDTA, 100 mM NaCl, 1 mM MgCl2,1m M
DTT, 4%(v/v) glycerol]. DNA concentrations were measured by
absorbance using a molar extinction coefﬁcient "260
1cmof 2.57   10
5.
Samples were stored at 253 K until use. EMSAs were carried out as
described by Hellman & Fried (2007) using 10%(w/v) polyacrylamide
gels cast and run in 45 mM Tris–borate, 2.5 mM EDTA (pH 8.3 at
293 K). Autoradiographic images were captured on storage phosphor
screens (type GP, GE Healthcare), detected with a Typhoon phos-
phorimager and quantitated with Image-Quanta software (GE
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Figure 1
The protein and DNA constructs used in characterization and crystallization. (a) Human HNF4 -DBD protein sequence. The predicted DNA-recognition helix is boxed and
the MODY mutations are shown in red. Cloning artifacts from the expression vector are indicated by lower case letters at the N-terminal end. (b) The natural HNF1 
promoter sequence ( 46 to  66; Gragnoli et al., 1997) containing the HNF4  recognition site used in crystallization and binding studies. Two direct-repeat half-sites are
boxed and the MODY mutation is shown in red.Healthcare). Data from serial dilution experiments were analyzed
using the equations
ln
½PnD 
½D 
¼ nln½P þlnKobs ð1Þ
and
½P ¼½ P tot   n½PnD : ð2Þ
Here, n is the binding stoichiometry, [PnD] and [D] the concentra-
tions of complex and free DNA, respectively, and Kobs =[ PnD]/
[P]
n[D]. When both n and Kobs are unknown (as in this case), iterative
calculation of n and [P] using (1) and (2) results in convergence on
self-consistent values of n and Kobs (Adams & Fried, 2007; Fried &
Crothers, 1984).
2.5. Dynamic light-scattering measurement
The effective molecular radius and the homogeneity/mono-
dispersity of the complex within various particular buffer conditions
were measured using the Solubility Screening Kit (Jena Biosciences)
in conjunction with a Dynapro-99 dynamic light-scattering instru-
ment (Proterion Corporation) and a DynaPro-MSTC200 micro-
sampler (Protein Solutions). The results were analyzed using
DYNAMICS v.5.26.60 (Protein Solutions). 20 ml of sample was
inserted into the cuvette with the temperature control set to 293 K.
The light-scattering signal was collected at a wavelength of 830.7 nm.
Protein concentrations were about 2 mg ml
 1 in each buffer and an
average of 15 readings were recorded for each measurement.
2.6. Crystallization and optimization
Protein–DNA complexes were dialyzed in 20 mM Tris pH 7.5,
75 mM NaCl and 1 mM DTTat 277 K for 2.5 h and concentrated to at
least 10 mg ml
 1. The initial crystallization trials were carried out at
295 K in 24-well plates using the hanging-drop vapor-diffusion
method with a sparse-matrix screen (Jancarik & Kim, 1991) and
similar commercially available versions such as Crystal Screens I and
II (Hampton Research), Natrix and PEG/Ion Screens (Hampton
Research), Cryo I and II (Molecular Dimensions) and Wizard I and II
(deCODE Genetics).
Drops consisting of 0.5 ml protein–DNA solution were mixed with
an equal volume of reservoir solution and equilibrated against 500 ml
reservoir solution. Although many different DNA constructs varying
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Figure 2
Gel ﬁltration of HNF4 -DBD with the molecular-weight standard samples
(labelled in kDa). HNF4 -DBD is homogeneous and appears to be a monomer
in solution. The SDS–PAGE of puriﬁed HNF4 -DBD along with the molecular-
weight standard is shown in the inset.
Figure 3
Binding of HNF4 -DBD to duplex 21-mer target DNA detected by EMSA.
Reactions were carried out in 10 mM Tris (pH 8.0 at 293 K), 1 mM EDTA, 100 mM
NaCl, 1 mM MgCl2,1 m M DTT, 4% glycerol, 100 mgm l
 1 BSA. (a) Forward
titration. All samples contained 0.21 mM duplex 21-mer. Samples contained
HNF4 -DBD protein, from the second lane, at 0.41, 0.82, 1.23, 2.05, 2.87, 3.69, 4.51,
5.33, 6.56, 8.2, 12.0 and 20.5 mM, respectively. (b) Serial dilution. The ﬁrst lane
contained reference DNA; the initial sample (second lane) contained 0.2 mM
duplex 21-mer and 17.9 mM HNF4 -DBD protein. Each succeeding lane contained
an aliquot of the previous sample diluted 1.2-fold. (c) Determination of
stoichiometry and association constant. Graph of ln[PnD]/[D] as a function of
ln[P]. The slope about the mid-point of the reaction (where ln[PnD]/[D] = 0) gives
the stoichiometry (n =2 . 3  0.2). The data used for this determination are indicated
by ﬁlled circles. The data near binding saturation (ﬁlled squares) deviate from the
linear relationship and were excluded from the ﬁt. A ﬁt of (1) to the linear data
returned an intercept value of ln[P]= 12.58   0.03, equivalent to Kobs = 8.48  
0.67   10
10 M
 2.in length and the nature of the ending (blunt end versus overhang)
were screened, diffraction-quality crystals were only reproducibly
obtained using the overhang 21-mer shown in Fig. 1(b) (the two
HNF4  direct-repeat recognition sites are indicated by the boxes).
Conditions yielding small crystals were further optimized by variation
of the crystallization parameters and additives. The ﬁnal condition,
which produced somewhat ﬂat bipyramidal crystals at 295 K,
contained 26%(v/v) PEG 4000, 80 mM magnesium acetate and
50 mM sodium citrate pH 4.8.
2.7. Data collection and processing
The crystals were transferred into mother liquor containing an
additional 15%(v/v) glycerol as a cryoprotectant before being directly
plunged into liquid nitrogen and stored for data collection. The native
data were collected at 100 K at APS (SER-CAT 22BM) using a MAR
225 CCD detector and an oscillation angle of 1  with 2 s exposure and
were processed using HKL-2000 (Otwinowski & Minor, 1997). The
wavelength used was 0.92017 A ˚ .
3. Results and discussion
Recombinant HNF4 -DBD (amino acids 46–126; Fig. 1a) was puri-
ﬁed to homogeneity and mixed with pure DNA for subsequent
studies. Gel-ﬁltration experiments showed that the HNF4 -DBD
protein existed as a monomer in solution (Fig. 2). Puriﬁed HNF4 -
DBD protein forms a single complex with DNA containing its target
sequence (Figs. 3a and 3b). Serial dilution analysis (Figs. 3b and 3c)
revealed that the stoichiometry of the complex was 2:1
HNF4 :dsDNA, with an association constant Kobs of 8.48   0.67  
10
10 M
 2. The corresponding monomer equivalent dissociation
constant was 3.43   0.13   10
 6 M. The formation of a 2:1 complex
without the accumulation of detectable levels of the 1:1 intermediate
indicates that binding is cooperative. These features will serve as a
reference when we study the effects of MODY mutations on DNA
binding in the near future.
Dynamic light scattering (DLS) is a useful tool to monitor protein
solubility behavior and to predict favorable crystallization conditions
(Wilson, 2003). We used the Solubility Screening Kit (Jena
Biosiences) in conjunction with DLS (Jancarik et al., 2004) in order to
identify the optimal buffer conditions for complex formation and
crystallization. The best polydispersity value of 0.06 was obtained
with a buffer containing 20 mM Tris pH 7.5 and 75 mM NaCl and this
optimal buffer was used for subsequent crystallization.
For crystallization, puriﬁed HNF4  46–126 and various DNAs
were simply mixed in a 2:1.2 molar ratio, dialyzed against the optimal
binding buffer (20 mM Tris pH 7.5, 75 mM NaCl) and concentrated
using 10 kDa molecular-weight cutoff concentrators (Millipore). The
protein–DNA concentration was 10 mg ml
 1 for initial screenings
and 20 mg ml
 1 for ﬁnal optimization. Crystals with the overhang
21-mer DNA (Fig. 1b) were grown at 295 K using the hanging-drop
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Figure 4
Typical crystals of the HNF4 –DNA complex.
Figure 5
A typical X-ray diffraction pattern from a crystal of the HNF4 –DNA complex. A small section near the water ring is enlarged and shown in the inset. The overall mosaicity
of the crystal was 0.3 .vapor-diffusion method and the presence of the HNF4 –DNA
complex in the crystals was conﬁrmed by running SDS–PAGE and
0.5%(w/v) agarose gels (data not shown). Crystals initially appeared
within 2 d and continued to grow until they reached average
dimensions of 0.05   0.1   0.2 mm (Fig. 4). A range of solution
conditions varying the pH, temperature and concentrations of addi-
tives such as organic solvents, divalent cations and polyamines were
used to attempt to improve the crystal quality. The ﬁnal optimized
condition contains 26%(v/v) PEG 4000, 80 mM magnesium acetate
and 50 mM sodium citrate pH 4.8. The best crystal diffracted to 2.0 A ˚
at the synchrotron source and belongs to space group C2, with unit-
cell parameters a = 121.63, b= 35.43, c= 70.99 A ˚ ,  = 119.36  (Fig. 5).
The value of the Matthews coefﬁcient (Matthews, 1968) is
2.12 A ˚ 3 Da
 1 for one complex (two HNF4  and one dsDNA) in the
asymmetric unit and the estimated solvent content is 41.6% based on
a protein speciﬁc density of 1.34. Final native data-collection statistics
are summarized in Table 1.
The structure was determined by molecular replacement using the
RXR–RAR–DNA complex structure (PDB code 1dsz) as a search
model and the program MOLREP (Vagin & Teplyakov, 1997) from
the CCP4 suite (Winn, 2003). An unambiguous solution was found
that gave an initial R value of 51.4% and a correlation coefﬁcient of
0.38 using data in the resolution range 15–3.0 A ˚ . The subsequent  A-
weighted 2Fo   Fc map after rigid-body reﬁnement clearly revealed
density corresponding to the structural differences between the
search model and the HNF4 –DNA complex. Model improvement
and reﬁnement of the structure are in progress.
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Table 1
Data-collection statistics for the HNF4 –DNA crystal.
Values in parentheses are for the highest resolution bin.
Space group C2
Unit-cell parameters (A ˚ ,  ) a = 121.63, b = 35.43,
c = 70.99,   = 119.36
Resolution (A ˚ ) 30.29–2.00 (2.07–2.00)
Observed reﬂections 94972
Unique reﬂections 17094
Redundancy 5.6 (3.6)
Completeness (%) 93.9 (72.4)
I/ (I) 12.1 (4.5)
Rmerge† (%) 6.4 (30.4)
Matthews coefﬁcient (A ˚ 3 Da
 1) 2.12
Solvent content (%) 41.61
Molecules per ASU One complex (2 HNF4 , 1 dsDNA)
† Rmerge =
P
hkl
P
i jIiðhklÞ h IðhklÞij=
P
hkl
P
i IiðhklÞ, where Ii(hkl) is the intensity of
reﬂection hkl,
P
hkl is the sum over all reﬂections and
P
i is the sum over i measurements
of reﬂection h.